CRBP
Corbus Pharmaceuticals Holdings, Inc.
There isn't enough reported data to score CRBP yet.
CRBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
CRBP's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
CRBP PE Valuation
CRBP has no meaningful PE right now: it lost money over the past year.
CRBP Forward outlook
There aren't enough analyst estimates for CRBP to show an outlook.
CRBP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$6.02 | -$0.49 |
| Q2 2026 | -$6.11 | -$1.33 |
| Q1 2026 | -$5.74 | -$1.50 |
| Q4 2025 | -$5.90 | -$2.22 |
| Q3 2025 | -$5.53 | -$0.90 |
| Q2 2025 | -$4.78 | +$0.97 |
| Q1 2025 | -$4.24 | +$2.66 |
| Q4 2024 | -$3.68 | +$6.63 |
CRBP is still losing money, but far less than before: $6.02 per share over the past year, against $53.40 at its worst in late 2020.
CRBP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2021 | $97.3K | -92% |
| Q2 2021 | $136.6K | -52% |
| Q1 2021 | $647.8K | -63% |
| Q4 2020 | $658.2K | -74% |
CRBP's revenue has slid since its 2019 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2021 | -14257% | -11496 points |
| Q2 2021 | -12230% | +1089 points |
| Q1 2021 | -2379% | -683 points |
| Q4 2020 | -3162% | -2105 points |
| Q3 2020 | -2761% | N/A |
| Q2 2020 | -13319% | N/A |
| Q1 2020 | -1696% | N/A |
| Q4 2019 | -1057% | N/A |
CRBP's operating margin was −14257% last quarter, down 11496 points from the same quarter a year ago, near the bottom of its range since 2019.
CRBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$21.3M | -$5.7M |
| Q2 2026 | -$29.6M | -$13M |
| Q1 2026 | -$25.6M | -$9.2M |
| Q3 2025 | -$15.6M | -$1.6M |
| Q2 2025 | -$16.6M | -$7.7M |
| Q1 2025 | -$16.4M | -$8.5M |
| Q4 2024 | -$10.9M | -$4.9M |
| Q3 2024 | -$13.9M | -$6.8M |
CRBP has burned cash in almost every quarter: −$92M over the past year, against −$58M the year before.
CRBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.4% | +1.4M shares |
| 1 year | +70% | +8.6M shares |
| 3 years | +398% | +16.7M shares |
| 5 years | +437% | +17M shares |
| Available history | +878% | +18.7M shares |
CRBP has 21M diluted shares, up 70% from a year ago.
CRBP Net Leverage
CRBP's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CRBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.5 | Oversold |
| Stochastic | 4.8 | Oversold |
CRBP's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
CRBP PE vs Healthcare Sector
CRBP has no meaningful PE right now: it lost money over the past year.
CRBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.74 | 28% below |
| 20 week MA | $7.61 | 55% below |
| 50 week MA | $8.42 | 60% below |
| 100 week MA | $9.05 | 62% below |
| 200 week MA | $14.9 | 77% below |
CRBP is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
CRBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $162.3 | $41.7 | -74% |
| 2021 | $41.7 | $21.0 | -50% |
| 2022 | $21.0 | $3.57 | -83% |
| 2023 | $3.57 | $6.04 | +69% |
| 2024 | $6.04 | $12.8 | +111% |
| 2025 | $12.8 | $8.33 | -35% |
| 2026 YTD | $8.33 | $3.41 | -59% |
CRBP's yearly returns have swung widely, from +111% in 2024 to −83% in 2022. It's down 59% so far in 2026.